Lagevrio

Molnupiravir, the active ingredient in Lagevrio, is an antiviral presented as a 200 mg capsule for oral use. It is indicated for the treatment of COVID‑19 in adults with mild to moderate disease who are at risk of progressing to severe illness.

GNH USA supplies Lagevrio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant shipments to a global network of healthcare providers, covering Europe, Asia, Africa and the Americas.

Lagevrio (molnupiravir) is an antiviral medication used to treat COVID‑19, an infection caused by the SARS‑CoV‑2 virus. - Mild to moderate COVID‑19 in adults at risk of severe disease: reduces the likelihood of hospitalization and death. - Early‑stage SARS‑CoV‑2 infection: helps limit viral replication when administered promptly after symptom onset. - Outpatient management of COVID‑19: provides an oral therapeutic option for patients not requiring immediate hospital care.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools occurring during treatment. - Headache: transient cranial discomfort. - Dizziness: occasional sense of light‑headedness. - Fatigue: feeling unusually tired. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or swelling. - Elevated liver enzymes: signs of hepatic stress. - Severe allergic reaction (anaphylaxis): rapid onset of breathing difficulty and swelling. - Hematologic abnormalities: rare changes in blood counts. - Acute pancreatitis: severe abdominal pain with nausea.

Before prescribing Lagevrio, clinicians should consider patient‑specific factors and monitor for adverse events. - Assess risk of progression: evaluate age, comorbidities, and vaccination status. - Renal function: use caution in patients with severe impairment. - Hepatic function: monitor liver enzymes during therapy. - Pregnancy and lactation: avoid use due to unknown safety profile. - Drug interactions: review concomitant medications for potential effects. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Lagevrio may interact with other medicines; monitoring is advised. Major Interactions (Avoid): - Co‑administration with other mutagenic antivirals: may increase risk of genomic toxicity. - Strong enzyme inducers (e.g., rifampicin): may reduce molnupiravir exposure. Moderate Interactions (Monitor Closely): - Immunosuppressants: monitor for increased infection risk. - Anticoagulants: observe for any changes in coagulation parameters. - Concomitant use of live vaccines: assess timing to avoid reduced vaccine efficacy.